Pharmaceutical

MYK-224 by Bristol-Myers Squibb for Diastolic Heart Failure (HFpEF): Likelihood of Approval

MYK-224 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diastolic Heart Failure (HFpEF).

Feb 16, 2024 - 18:00
MYK-224 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diastolic Heart Failure (HFpEF).
Read the original article

Tags:

Previous Article

Psychedelic treatments for mental health: Is there substance behind the hype?

Next Article

Trial for Gritstone’s BARDA-funded COVID-19 vaccine delayed due to production is...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Should ACA plans cover weight loss drugs?

Should ACA plans cover weight loss drugs?

Feb 21, 2024

Bayer applies for EU approval of menopause drug elinzanetant

Bayer applies for EU approval of menopause drug elinzan...

Oct 16, 2024

A chatbot that’s cautious about GPT, AI pronouncements, and a VC looks to Israel

A chatbot that’s cautious about GPT, AI pronouncements,...

Jun 16, 2023